Imagen de Portada

T Cell‐Independent Role of PD‐L1 in Kidney Repair: Mitigation of Tubular DNA Damage via PD‐L1/BRCA1 Interaction Following AKI

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei Jiang, Tao‐Tao Tang, Wei‐Jie Ni, Jin‐Xuan Wei, Liang‐Yun‐Zi Jiang, Qing Yin, Yi‐Lin Zhang, Zuo‐Lin Li, Yi Wen, Xin‐Lu Wang, Jun‐Yuan Shen, Xiao‐Jun Ouyang, Ming‐Zhu Zheng, Jian Xu, Xiaofei An, Lin‐Li Lv, Bi‐Cheng Liu, Bin Wang
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Advanced Science
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
por: Li Li, et al.
Publicado: (2024)

Insulin‐Like Growth Factor 1 Receptor Expression for Predicting PD‑1/PD‑L1 Inhibitor Response in Hypopharyngeal Squamous Cell Carcinoma
por: Wen‐Jing Li, et al.
Publicado: (2025)

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
por: Xintong Li, et al.
Publicado: (2024)

STK25 Loss Augments Anti‐PD‐1 Therapy Efficacy by Regulating PD‐L1 Stability in Colorectal Cancer
por: Xiaowen Qiao, et al.
Publicado: (2025)

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer
por: Hao Wang, et al.
Publicado: (2025)

PD‐L1 Acts Independently of PD‐1 as a Marker of Pathologic Fibroblasts in Laryngotracheal Stenosis
por: Ruth J. Davis, et al.
Publicado: (2024)

Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy
por: Yi Zhu, et al.
Publicado: (2026)

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
por: Peng Gao, et al.
Publicado: (2025)

Exploring the Functional Role of Programmed Death‐Ligand 1 ( PD ‐ L1 ) in the Castration‐Resistant Prostate Cancer Using Transcriptomic Sequencing Analysis
por: Lin Zhong, et al.
Publicado: (2025)

Comparative efficacy and safety of PD‐1 versus PD‐L1 inhibitors in breast cancer treatment: A systematic review and meta analysis
por: Xintong Xie, et al.
Publicado: (2024)

The interaction of PD ‐1/ PD ‐ L1 and its inhibition by anti‐ PD ‐ L1 antibody at the single‐molecule level
por: Yonghui Zhang, et al.
Publicado: (2025)

HIF‐1α and adaptor protein LIM and senescent cell antigen‐like domains protein 1 axis promotes tubulointerstitial fibrosis by interacting with vimentin in angiotensin II‐induced hypertension
por: Wei‐Jie Ni, et al.
Publicado: (2024)

Identification of a Novel ECM Remodeling Macrophage Subset in AKI to CKD Transition by Integrative Spatial and Single‐Cell Analysis (Adv. Sci. 38/2024)
por: Yi‐Lin Zhang, et al.
Publicado: (2024)

Age‐Associated Targetable Genomic Alterations and PD ‐ L1 Expression in 2509 Patients With Pulmonary Ground‐Glass Opacities
por: Wen‐Fang Tang, et al.
Publicado: (2026)

Miniprotein engineering for inhibition of PD‐1/PD‐L1 interaction
por: Agnieszka Ciesiołkiewicz, et al.
Publicado: (2024)

Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD ‐ L1 Pathways
por: Hui‐Hsin Ko, et al.
Publicado: (2025)

Linarin Suppresses the Progression of Colorectal Cancer by Inhibiting the HIF‐1α/PD‐L1 Axis
por: Hao Wang, et al.
Publicado: (2025)

High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay
por: Shuai Zhen
Publicado: (2025)

Clinical Benefit of PD‐1/PD‐L1 Inhibitors as Standard First‐Line Treatment in Low PD‐L1‐Expressing Advanced Solid Tumors: A Systematic Review and Meta‐Analysis
por: Peng Wu, et al.
Publicado: (2026)

Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis
por: Ning Wang, et al.
Publicado: (2024)

Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells
por: Jin Lei, et al.
Publicado: (2024)

Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition
por: Bai‐Xue Yu, et al.
Publicado: (2024)

TWIST1 Activates CDCA3 to Promote EMT of Lung Adenocarcinoma and Expression of PD‐L1
por: Jianyi Ding, et al.
Publicado: (2026)

Oxaliplatin/Norcantharidin Prodrug Co‐Loaded Nanoparticles: Synergistic DNA‐Repair Blockade Plus PD‐L1 Downregulation for Inhibit Tumor Growth and Metastasis
por: Peng‐Wei Chen, et al.
Publicado: (2026)

Heteronemin suppresses EGF‑induced proliferation through the PI3K/PD‑L1 signaling pathways in cholangiocarcinoma.
por: Yang, Yu-Chen S H, et al.
Publicado: (2025)

A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance
por: Lei Yi, et al.
Publicado: (2024)

Immune Modulatory Effects of PD ‐1/ PD ‐ L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis
por: Jianing Li, et al.
Publicado: (2025)

HIF‐1α and PD‐L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer
por: Lin Lu, et al.
Publicado: (2026)

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation
por: Shaoqing Huang, et al.
Publicado: (2026)

The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer
por: Hao Hu, et al.
Publicado: (2024)

Characteristics of Soluble PD‐L1 and PD‐1 Expression and Their Correlations With Immune Status and Prognosis in Advanced Lung Cancer
por: Ran Li, et al.
Publicado: (2025)

Dynamic Change of PD‐L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti‐PD‐1 Therapy
por: Linzi Sun, et al.
Publicado: (2025)

Case Report of Acute Central Airway Obstruction Induced by Anti‐ PD ‐1 Sintilimab: Clinical Presentation and Review
por: Ting Ouyang, et al.
Publicado: (2026)

Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
por: Kazumasa Oya, et al.
Publicado: (2024)

CD27 and ICOS as Targets of PD‐1/PD‐L1 Signaling to Regulate Resident Memory CD8 + T‐Cell‐Mediated Pulmonary Protection and Pathology
por: Yuanyuan Chen, et al.
Publicado: (2025)

Small‐Molecule Inhibitors Targeting PD‐1/PD‐L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects
por: Jianwei Wang, et al.
Publicado: (2025)

Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study
por: Tao Ning, et al.
Publicado: (2024)

Design, Synthesis, and Biological Evaluation of Small‐Molecule PD‐1/PD‐L1 Inhibitors Bearing a Rigid Benz[d]oxazole Skeleton
por: Bo Wei, et al.
Publicado: (2026)

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma
por: Kaifeng Jin, et al.
Publicado: (2024)

Exosomal miR‐142‐3p from M1‐polarized macrophages suppresses cell growth and immune escape in glioblastoma through regulating HMGB1‐mediated PD‐1/PD‐L1 checkpoint
por: Yigong Wei, et al.
Publicado: (2024)